Engineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery

Area of Science:

• Immunology
• Nanotechnology
• Vaccinology

Background:

• Respiratory mucosal vaccination offers superior protection against viral infections by inducing immunity at the pathogen's entry site.
• Messenger RNA (mRNA) vaccines are promising due to rapid development and potent immunogenicity.
• Challenges in respiratory mRNA delivery include biological barriers and formulation instability.

Purpose of the Study:

• To evaluate nanoparticle engineering strategies for overcoming respiratory mucosal barriers for mRNA vaccines.
• To assess improvements in safety, stability, delivery efficiency, and immunogenicity of mRNA vaccines via nanoparticles.
• To review advancements in nanoparticle platforms for respiratory mucosal mRNA immunization.

Main Methods:

• Summarizing recent progress in engineered mRNA nanoparticle platforms.
• Encompassing modified lipid nanoparticles (LNPs), polymer-based nanoparticles, and hybrid systems (lipid-inorganic, polymeric, lipid-extracellular vesicle).
• Discussing optimization strategies like adjuvants, PEG alternatives, and advanced delivery methods.

Main Results:

• Nanoparticle engineering addresses challenges in mRNA stability, cellular uptake, and immune response.
• Various nanoparticle systems (LNPs, polymer, hybrid) show potential for mucosal delivery.
• Optimization strategies enhance mucosal mRNA delivery and immunogenicity.

Conclusions:

• Nanoparticle engineering is crucial for developing effective mRNA vaccines for respiratory mucosal delivery.
• Overcoming biological barriers with advanced platforms can lead to durable and broad mucosal immunity.
• Future research should focus on rational design of next-generation mRNA nanoparticle platforms for respiratory viral infections.